What is the CJC-1295 + Ipamorelin combination and why are they studied together?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized by DAC (drug affinity complex) technology, which significantly extends its plasma half-life by forming a covalent bond with albumin. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic — that stimulates pituitary GH release through a separate receptor pathway. Combining GHRH analog and GHSR agonist targets both primary regulatory inputs to pituitary somatotrophs, producing synergistic GH pulses in preclinical studies that are larger than either peptide alone while maintaining the physiological pulsatility that distinguishes this approach from continuous exogenous GH administration.

Source: J Clin Endocrinol Metab (2006) · PubMed

CJC-1295 + Ipamorelin — 10mg (5mg + 5mg), 99.3% purity →

Summarised from peer-reviewed literature for research reference. For laboratory research use only.